Earnings Results
Palisade Bio (NASDAQ:PALI) reported quarterly earnings results on November 10, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-0.07, missing the consensus estimate of $-0.06 by $0.01 per share. Revenue came in at , meeting the estimate of .
Company Overview
Palisade Bio's stock moved following the earnings release. The stock currently trades at $1.17 with a market capitalization of $327.1M.
Missing analyst estimates puts pressure on a stock as investors reassess their growth assumptions. The market's reaction to an earnings miss depends heavily on the magnitude of the shortfall, the company's forward guidance, and whether the miss was driven by temporary or structural factors.
The 17% miss relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Palisade Bio should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.
Palisade Bio Earnings History
| Quarter | EPS Actual | EPS Est. | Surprise |
| Q3 (Nov 2026) | $-0.07 | $-0.06 | -16.7% |
| Q2 (Aug 2026) | $-0.05 | $-0.05 | +0.0% |
| Q1 (May 2026) | $-0.05 | $-0.04 | -25.0% |
Related Tools: Earnings Calendar | View PALI Stock Page
Frequently Asked Questions
When does Palisade Bio report earnings?
Check the latest earnings dates on our PALI earnings page or the Earnings Calendar.
Did PALI beat earnings estimates?
See the full Q3 results including EPS actual vs estimate on our PALI earnings page.